Dianthus Therapeutics, Inc. /DE/
DNTHNasdaq
$105.60
↑ +10.7%Jul 17 close · end-of-day
Price
1Y↑ +432.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.1B
Enterprise Value
$4.0B
P/E
—
P/S
—
P/B
4.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
0.0%
Revenue (TTM)
—
Net Income (TTM)
-$173.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-14.5%
ROIC
-167.8%
Debt / Equity
—
Net Cash
$1.1B
Return 1Y
+418.9%
Company profile
Magenta Therapeutics develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy.
- CEO
- Jason Gardner
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- New York
- Website
- magentatx.com
Management & directors
- Savitz RyanEVP, CFO & CBO
- Veness Adam MSVP, General Counsel and Sec.
- Randhawa SimratEVP, Head of R&D
- Garcia MarinoCEO AND PRESIDENT
- Carr EdwardCHIEF ACCOUNTING OFFICER
Roles derived from SEC Form 4 filings.
Earnings
DNTH Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.85↑ +3.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $1.5M | $6.4M | $2.8M | $6.2M | $2.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$78.7M | -$13.1M | -$29.7M | -$48.2M | -$101.9M | -$177.9M |
| Net income | -$74.9M | -$13.1M | -$28.5M | -$43.5M | -$85.0M | -$162.3M |
| Diluted EPS | -$1.71 | -$15.01 | -$32.57 | -$8.45 | -$2.55 | -$4.20 |
| Operating cash flow | -$64.0M | -$9.9M | -$29.1M | -$36.9M | -$78.2M | -$129.1M |
| Free cash flow | -$64.4M | -$11.2M | -$29.4M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -886.6% | -462.9% | -1704.7% | -1633.7% | -8739.3% |
| Net margin | — | -888.1% | -443.8% | -1540.9% | -1362.8% | -7973.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $2.2M | $1.3M | $1.2M | $193,000.00 | $396,000.00 | $284,000.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$22.2M | -$29.9M | -$31.9M | -$33.2M | -$34.9M | -$40.3M | -$69.5M | -$46.5M |
| Net income | -$17.6M | -$25.2M | -$28.4M | -$29.5M | -$31.6M | -$36.8M | -$64.4M | -$40.8M |
| Diluted EPS | -$0.51 | -$0.74 | -$0.76 | -$0.82 | -$0.88 | -$0.97 | -$1.53 | -$0.85 |
| Operating cash flow | -$14.5M | -$21.3M | -$27.4M | -$27.6M | -$23.9M | -$30.6M | -$47.0M | -$28.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1191.8% | -1376.6% | -2406.9% | -2852.7% | -18096.9% | -10173.7% | -24486.3% | — |
| Net margin | -945.1% | -1159.0% | -2144.8% | -2537.5% | -16388.1% | -9284.1% | -22687.3% | — |
Company news
Jun 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-09 | Savitz Ryan· EVP, CFO & CBO | Sale | 15,329 | $101.24 | $1.6M | filing |
| 2026-07-09 | Savitz Ryan· EVP, CFO & CBO | Sale | 10,354 | $100.22 | $1.0M | filing |
| 2026-07-09 | Savitz Ryan· EVP, CFO & CBO | Option exercise | 31,249 | $21.77 | $680,290.73 | filing |
| 2026-07-09 | Savitz Ryan· EVP, CFO & CBO | Sale | 5,566 | $101.97 | $567,565.02 | filing |
| 2026-06-17 | Veness Adam M· SVP, General Counsel and Sec. | Sale | 16,771 | $80.34 | $1.3M | filing |
| 2026-06-17 | Veness Adam M· SVP, General Counsel and Sec. | Sale | 13,229 | $81.38 | $1.1M | filing |
| 2026-06-17 | Veness Adam M· SVP, General Counsel and Sec. | Option exercise | 30,000 | $17.88 | $536,400.00 | filing |
| 2026-06-01 | Randhawa Simrat· EVP, Head of R&D | Sale | 16,943 | $90.72 | $1.5M | filing |
| 2026-06-01 | Randhawa Simrat· EVP, Head of R&D | Sale | 5,428 | $89.72 | $487,000.16 | filing |
| 2026-06-01 | Randhawa Simrat· EVP, Head of R&D | Sale | 4,159 | $91.37 | $380,007.83 | filing |
| 2026-06-01 | Randhawa Simrat· EVP, Head of R&D | Option exercise | 9,375 | $22.07 | $206,906.25 | filing |
| 2026-06-01 | Randhawa Simrat· EVP, Head of R&D | Option exercise | 6,249 | $21.77 | $136,040.73 | filing |
| 2026-06-01 | Randhawa Simrat· EVP, Head of R&D | Option exercise | 6,908 | $17.88 | $123,515.04 | filing |
| 2026-06-01 | Randhawa Simrat· EVP, Head of R&D | Option exercise | 3,998 | $8.44 | $33,743.12 | filing |
| 2026-05-08 | Soteropoulos Paula | Sale | 599 | $85.47 | $51,196.53 | filing |
| 2026-05-08 | Soteropoulos Paula | Option exercise | 599 | $8.44 | $5,055.56 | filing |
| 2026-04-09 | Savitz Ryan· EVP, CFO & CBO | Sale | 8,224 | $89.84 | $738,844.16 | filing |
| 2026-04-09 | Savitz Ryan· EVP, CFO & CBO | Option exercise | 8,224 | $17.88 | $147,045.12 | filing |
| 2026-03-31 | Savitz Ryan· EVP, CFO & CBO | Sale | 59,800 | $83.90 | $5.0M | filing |
| 2026-03-31 | Savitz Ryan· EVP, CFO & CBO | Sale | 21,825 | $78.86 | $1.7M | filing |
| 2026-03-31 | Savitz Ryan· EVP, CFO & CBO | Sale | 19,469 | $84.57 | $1.6M | filing |
| 2026-03-31 | Savitz Ryan· EVP, CFO & CBO | Option exercise | 40,000 | $17.88 | $715,200.00 | filing |
| 2026-03-31 | Savitz Ryan· EVP, CFO & CBO | Option exercise | 74,367 | $8.44 | $627,657.48 | filing |
| 2026-03-31 | Savitz Ryan· EVP, CFO & CBO | Sale | 7,232 | $85.54 | $618,625.28 | filing |
| 2026-03-31 | Savitz Ryan· EVP, CFO & CBO | Sale | 2,366 | $82.84 | $195,999.44 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.